Safe and short time treatment of superficial and unresectable deep tumors

Clinical trial of local and short time treatment of superficial and visceral tumors using electrochemical method Based on a needle wire without any destructive effect for healthy tissues

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190904044697N5

Enrollment

Registered

2020-04-17

Start date

2020-03-10

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Malignant cancer with solid tumor. Condition 2: Benign tumor with solid mass. Condition 3: Malignant cancer with solid tumor. Condition 4: Benign tumor with solid mass. Condition 5: Malignant cancer with solid tumor. Condition 6: Malignant cancer with solid tumor. Condition 7: Malignant cancer with solid tumor. Condition 8: Malignant cancer with solid tumor. Condition 9: Malignant cancer with solid tumor. Condition 10: Malignant cancer with solid tumor. Condition 11: Malignant cance

Interventions

Intervention 1: Intervention group: Patients with all types of benign and malignant carcinoma tumors with evaluable solid mass that were nominated in this study according to inclusion criteria will un

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cancer patients who have different types of cancer with solid tumors. Patients who the biopsy results of their tumors approved that the tumors are malignant Patients with any superficial and unresectable deep tumors Patients with highest levels of invasion are more appropriate for receiving treatment (i.e. triple negative breast cancer and gastrointestinal invasive cancers) Pathological or radiological evidence of progression of the disease despite common treatments Patients with end-stage cancer who oncologists confirm that they did not profit from an alternative treatment, can include the study as a palliative therapy Patients with different types of benign and malignant tumors

Exclusion criteria

Exclusion criteria: Patients who do not have a definable and discriminating mass to evaluate response to treatment. pregnancy Patients who do not have appropriate general condition and need intensive care.

Design outcomes

Primary

Measure	Time frame
Changes in the size and extent of tumor necrosis. Timepoint: one week. Method of measurement: Imaging modalities (Conventional ultrasound and especially Doppler ultrasound, MRI and CT scan), Immunohistochemistry, pathological and microscopical markers and cellular staining.;Clinical and quality of life changes. Timepoint: Every day. Method of measurement: Blood Test, Investigating of Clinical Manifestation.	—

Measure

Time frame

Changes in the size and extent of tumor necrosis. Timepoint: one week. Method of measurement: Imaging modalities (Conventional ultrasound and especially Doppler ultrasound, MRI and CT scan), Immunohistochemistry, pathological and microscopical markers and cellular staining.;Clinical and quality of life changes. Timepoint: Every day. Method of measurement: Blood Test, Investigating of Clinical Manifestation.

—

Secondary

Measure	Time frame
Quality Of Life. Timepoint: 90 days. Method of measurement: Questionnaire about quality of life indicators based on EORTC QLQ-C30.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Abdolahad

Tehran University of Medical Sciences

m.abdolahad@ut.ac.ir+98 21 8802 8367

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026